Refractory IBD: The Case for Doubling Up on Drugs

(MedPage Today) -- Dual biologic or small molecule therapy may benefit highly selected, refractory inflammatory bowel disease (IBD) patients at specialized centers, a meta-analysis suggested.
In a review of 30 studies reporting on 288 trials...